19th IDS Congress
Paris 2023
23-27 May. 2023
The Immunology of Diabetes Society (IDS) is a scientific society dedicated to improving understanding and treatment of type 1 diabetes. IDS organizes a Congress every 18 months in major centres in Europe, North America and Asia/Oceania at which there are scientific presentations to further this goal.
Centre international de Conférences Sorbonne Université
4 place Jussieu - 44-55
75005 - Paris, France
*To submit before 15th February 2023
Confirmed Speakers
(by alphabetical order)
Peter Achenbach, Mark Atkinson, Jean-François Bach, Burkhard Becher, Polly Bingley, Christian Boitard, Ezio Enrico Bonifacio, Marcela Brissova, Todd Brusko, Jenny Couper, Mark M. Davis, Gerard Eberl, Decio L. Eizirik, Donna Farber, Carla Greenbaum, John Harris, Len Harrisson, Matthias Hebrok, Kevan Herold, Heikki Hyoty, Sally Kent, David Klatzmann, Aaron J. Kowalski, Jeffrey Krischer, Vito Lampasona, Peter E. Lipsky, Chantal Mathieu, Eoin McKinney, Gerald T. Nepom, Maria Cristina Nostro, Timo Otonkoski, Alberto Pugliese, Frédéric Rieux-Laucat, Bart Roep, Miguel Sanjuan, Pere Santamaria, Andrea Schietinger, Anath Shalev, Tommi Suvitaival, Qizhi Tang, Timothy Tree, Tommi Vatanen, Carola Vinuesa, John Wentworth, Benjamin Youngblood, Anette Ziegler
Friday 26th
8.20 am
Plenary 4
Circulating vs tissue immune cells: Donna Farber (Columbia University, New York)
9.00 am
11.00 am
Short Symposium 6: Theme to be defined
Talk 23
Talk 24
Oral Abstract 20
Oral Abstract 21
Oral Abstract 22
Short Symposium 5: Blood omics
Talk 21: Sense and non-sense of multi-omics screening strategies in T1D: Tim Tree (King’s College, London)
Talk 22: CyTOF/RNAseq biomarkers in TrialNet/TEDDY at-risk subjects: Eoin McKinney (University of Cambridge)
Oral Abstract 17
Oral Abstract 18
Oral Abstract 19
12.30 am
Antibody Workshop session – Chairs: Peter Achenbach, Vito Lampasona
1.30 - 2.30 pm
Lunch
10.30 - 11 am
Break
2.30 pm
5.00 pm
Long Symposium 5: Trials with new results
Talk 25: Coxsackievirus vaccination trial: Miguel Sanjuan (Provention)
Talk 26: Baricitinib in new-onset T1D: John Wentworth (University of Melbourne)
Talk 27: ActoBio Lactococcus lactis / Teplizumab: Chantal Mathieu (UZ Leuven)
Talk 28: Teplizumab update & biomarkers in TN10 prevention trial: Kevan Herold (Yale University, New Haven)
Talk 29: Low-dose IL-2, DIAB-IL2 trial: David Klatzmann (Sorbonne University, Paris)
Talk 30: Wrap-up: how good is good enough? Challenges and realities of T1D prevention/intervention: Anette Ziegler (Helmholtz, Munich)
Debate 2: type 1 diabetes endotypes: age and beyond
It all comes to age: Ezio Bonifacio (TUD, Dresden)
It is much more than age: Carla Greenbaum (Benaroya Research Institute, Seattle)
6.00 pm
6.30 pm
Poster Blast 3 (31 to 45)
90” and 1 plain slide/each
Poster Session 3 (31 to 45)
90” and 1 plain slide/each